Skip to main content

Table 1 Comparison of FAM19A4 methylation in hrHPV–positive samples with differing severity of cervical lesions

From: The clinical significance of FAM19A4 methylation in high-risk HPV-positive cervical samples for the detection of cervical (pre)cancer in Chinese women

Results

Median Methylation

Methylation Rates

cOR

aOR

Category

Scores(\( \mathrm{P}\frac{1}{4}-\mathrm{P}\frac{3}{4} \))

(%)

(95%CI)

(95%CI)

Cervical cancer

141.42(59.95–389.23)

93.44(57/61)

120.11(33.35–432.53)

59.171(14.911–234.801)

HSIL a

5.36(0.48–43.70)

56.14(32/57)

10.79(4.21–27.68)

9.061(3.208–25.596)

LSIL b

2.27(0.23–9.79)

35.48(11/31)

4.64(1.58–13.58)

4.862(1.542–15.324)

No CIN c,d

0.74(0.002–5.70)

10.61(7/66)

1.00

1.00

  1. The cOR was calculated by multinomial regression analysis, using four different types of cervical lesions as the dependent variables, FAM19A4 methylation(positive or negative) as an independent variable
  2. The aOR was calculated by multinomial regression analysis, correcting other factors of ages, HPV genotyping(HPV16/18 or non-HPV16/18) and cytology(<ASC-US or ≥ ASC-US), and also used four different types of cervical lesions as the dependent variables, FAM19A4 methylation(positive or negative) as an independent variable
  3. P percentiles, CI confidence interval, cOR crude odds ratio, aOR adjusted odds ratio
  4. Methylation scores were used to calculate the statistical difference
  5. a: compared with cervical cancer, H = 85.55, P < 0.0001, Kruskal-Wallis H Test
  6. b: compared with cervical cancer, H = 116.21, P < 0.0001, Kruskal-Wallis H Test
  7. c: compared with cervical cancer, H = 122.11, P < 0.0001, Kruskal-Wallis H Test
  8. d: compared with HSIL, H = 36.551, P < 0.05, Kruskal-Wallis H Test
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us